论文部分内容阅读
作者通过采用将编码粘膜免疫原的基因融合到霍乱毒素(CT)A2亚单位基因(A2亚单位与一种有效免疫增强因子CTB亚单位相连)的方法开发了一种适合口服免疫的方案.用于评估的基于非毒性CTA2/B构建体的口服免疫原来自于变异链球菌AgⅠ/Ⅱ粘附素的唾液结合区(SBR).SBR与CTA2/B相连构成SBR-CT~(△Al).口服接种证实这种抗原有免疫原性,可诱生高水平的抗AgⅠ/Ⅱ分泌性IgA(S-IgA)及血清IgG抗体.作者对小鼠口服SBR-CT~(△Al)抗原后产生的抗AgⅠ/Ⅱ粘附素抗体应答进行了评估.第1组5只小鼠,口服3剂100μgSBR-CT~△Al及μg完整CT(作为佐剂);第2组3只小鼠,仅口服3剂SBR-CT~△Al;第3组6只小鼠,口服缓冲液作为对照.于末次免疫后11个月收集唾液和血清标本,并用100μgSBR-CT~(△Al)胃内加强接种所有小鼠,同时给予第1组小鼠及半数对照组小鼠CT佐剂5μg.于加强免疫后7天收集血清和唾液标本,用ELISA测定抗体应答.
The authors developed a protocol for oral immunization by using a method of fusion of the gene encoding the mucosal immunogen to the cholera toxin (CT) A2 subunit gene (A2 subunit linked to an effective immunopotency factor CTB subunit) The oral immunogen for the non-toxic CTA2 / B construct evaluated was derived from the salivary binding domain (SBR) of Streptococcus mutans AgI / II adhesins, which linked to CTA2 / B to form SBR-CT to (Al). Oral vaccination confirmed that this antigen is immunogenic, can induce high levels of anti-Ag Ⅰ / Ⅱ secreted IgA (S-IgA) and serum IgG antibody in mice oral administration of SBR-CT ~ (△ Al) antigen Anti-Ag I / II antibody responses were evaluated in group 1. Group 1 5 mice were orally given 3 doses of 100 [mu] g SBR-CT to [Delta] Al and [mu] g complete CT as adjuvant; Group 2, 3 mice, Saline and serum samples were collected at 11 months after the last immunization and inoculated with 100 μg SBR-CT (△ Al) intragastric inoculation All mice were given concurrently 5 μg of CT adjuvant to mice in group 1 and to half of control mice Serum and saliva samples were collected 7 days after booster immunization and were assayed by ELISA Body response.